Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Debt: 2009-2011

Historic Current Debt for Cytokinetics (CYTK) over the last 2 years, with Mar 2011 value amounting to $180.9 million.

  • Cytokinetics' Current Debt rose 2.60% to $180.9 million in Q1 2011 from the same period last year, while for Mar 2011 it was $167.7 million, marking a year-over-year decrease of 54.60%. This contributed to the annual value of $174.6 million for FY2010, which is 49.89% up from last year.
  • Per Cytokinetics' latest filing, its Current Debt stood at $180.9 million for Q1 2011, which was up 150.68% from -$356.8 million recorded in Q4 2010.
  • In the past 5 years, Cytokinetics' Current Debt ranged from a high of $185.3 million in Q3 2009 and a low of -$356.8 million during Q4 2010.
  • For the 3-year period, Cytokinetics' Current Debt averaged around $67.1 million, with its median value being $171.8 million (2010).
  • Within the past 5 years, the most significant YoY rise in Cytokinetics' Current Debt was 5,664.09% (2010), while the steepest drop was 5.50% (2010).
  • Cytokinetics' Current Debt (Quarterly) stood at $185.3 million in 2009, then declined by 5.50% to -$356.8 million in 2010, then grew by 2.60% to $180.9 million in 2011.
  • Its last three reported values are $180.9 million in Q1 2011, -$356.8 million for Q4 2010, and $175.1 million during Q3 2010.